Vigil Neuroscience (VIGL) Competitors $1.70 +0.04 (+2.41%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VIGL vs. CCCC, FDMT, ITOS, ENGN, ATYR, ARTV, IKT, OCGN, LXEO, and FATEShould you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include C4 Therapeutics (CCCC), 4D Molecular Therapeutics (FDMT), iTeos Therapeutics (ITOS), enGene (ENGN), Atyr PHARMA (ATYR), Artiva Biotherapeutics (ARTV), Inhibikase Therapeutics (IKT), Ocugen (OCGN), Lexeo Therapeutics (LXEO), and Fate Therapeutics (FATE). These companies are all part of the "biological products, except diagnostic" industry. Vigil Neuroscience vs. C4 Therapeutics 4D Molecular Therapeutics iTeos Therapeutics enGene Atyr PHARMA Artiva Biotherapeutics Inhibikase Therapeutics Ocugen Lexeo Therapeutics Fate Therapeutics C4 Therapeutics (NASDAQ:CCCC) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, community ranking, risk and institutional ownership. Which has more volatility & risk, CCCC or VIGL? C4 Therapeutics has a beta of 2.92, suggesting that its share price is 192% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Which has better earnings and valuation, CCCC or VIGL? Vigil Neuroscience has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$33.67M8.28-$132.49M-$1.70-2.32Vigil NeuroscienceN/AN/A-$82.64M-$2.06-0.83 Do institutionals and insiders hold more shares of CCCC or VIGL? 78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are owned by institutional investors. 8.6% of C4 Therapeutics shares are owned by company insiders. Comparatively, 33.0% of Vigil Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to CCCC or VIGL? In the previous week, C4 Therapeutics had 4 more articles in the media than Vigil Neuroscience. MarketBeat recorded 7 mentions for C4 Therapeutics and 3 mentions for Vigil Neuroscience. Vigil Neuroscience's average media sentiment score of 1.30 beat C4 Therapeutics' score of 1.05 indicating that Vigil Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vigil Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer CCCC or VIGL? Vigil Neuroscience received 2 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 82.86% of users gave Vigil Neuroscience an outperform vote while only 39.13% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2739.13% Underperform Votes4260.87% Vigil NeuroscienceOutperform Votes2982.86% Underperform Votes617.14% Is CCCC or VIGL more profitable? Vigil Neuroscience has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Vigil Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% Vigil Neuroscience N/A -83.89%-65.34% Do analysts recommend CCCC or VIGL? C4 Therapeutics currently has a consensus price target of $10.67, indicating a potential upside of 170.04%. Vigil Neuroscience has a consensus price target of $19.75, indicating a potential upside of 1,061.76%. Given Vigil Neuroscience's stronger consensus rating and higher possible upside, analysts clearly believe Vigil Neuroscience is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Vigil Neuroscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVigil Neuroscience beats C4 Therapeutics on 11 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIGL vs. The Competition Export to ExcelMetricVigil NeuroscienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$69.49M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.8346.7390.1317.19Price / SalesN/A415.011,116.25117.01Price / CashN/A182.1043.1037.85Price / Book0.523.894.784.78Net Income-$82.64M-$42.21M$120.31M$225.60M7 Day Performance-14.57%-2.15%-1.92%-1.23%1 Month Performance-46.71%1.73%13.65%0.46%1 Year Performance-54.05%16.36%28.34%15.24% Vigil Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIGLVigil Neuroscience3.7919 of 5 stars$1.70+2.4%$19.75+1,061.8%-52.5%$69.49MN/A-0.8364Positive NewsGap UpHigh Trading VolumeCCCCC4 Therapeutics2.0584 of 5 stars$4.28-2.3%$10.00+133.6%-11.2%$302.12M$33.67M-2.58150Analyst UpgradeNews CoverageGap DownFDMT4D Molecular Therapeutics2.7649 of 5 stars$6.53+0.5%$42.13+545.1%-69.1%$301.87M$17,000.00-2.28201Analyst ForecastITOSiTeos Therapeutics3.5048 of 5 stars$7.72+0.5%$25.25+227.1%-28.8%$282.04M$35M-2.4490Analyst ForecastENGNenGene3.0006 of 5 stars$6.17+1.5%$30.38+392.3%-19.4%$272.81MN/A-3.7331Earnings ReportNews CoveragePositive NewsGap UpATYRAtyr PHARMA2.4718 of 5 stars$3.06flat$19.25+529.1%N/A$256.86M$235,000.00-3.2656News CoverageARTVArtiva BiotherapeuticsN/A$10.32-2.8%$21.25+105.9%N/A$250.67MN/A0.0081Positive NewsIKTInhibikase Therapeutics1.5767 of 5 stars$3.71+7.8%$6.50+75.2%+154.0%$249.29M$260,000.00-1.448High Trading VolumeOCGNOcugen1.2391 of 5 stars$0.85-1.0%$5.67+567.7%+89.5%$247.24M$4.70M-4.7665News CoverageGap DownLXEOLexeo Therapeutics2.2141 of 5 stars$7.01+1.9%$23.80+239.5%-57.2%$231.79M$650,000.00-2.1858News CoverageGap DownFATEFate Therapeutics3.5395 of 5 stars$2.02+10.1%$6.75+235.0%-49.9%$229.50M$13.45M-1.22550 Related Companies and Tools Related Companies CCCC Competitors FDMT Competitors ITOS Competitors ENGN Competitors ATYR Competitors ARTV Competitors IKT Competitors OCGN Competitors LXEO Competitors FATE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VIGL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
